PANEL: Pre-approval Access for rare diseases, current considerations

PANEL: Pre-approval Access for rare diseases, current considerations

Wednesday, November 4, 2020 1:10 PM to 2:10 PM · 1 hr. (Africa/Abidjan)
Access & Pricing

Information

  •   What are strategic considerations for Expanded Access within the rare diseases space? 
  • What are recent developments and experiences with Expanded Access within the EU? 
  • How can EA Pathways can be supportive of high-cost therapies - some new developments here? 
  • What would be the role of Real-World Data – any considerations? 
  • What are key learnings from COVID-19 as an industry?  
  • Any regulatory trends that would be supportive of pre-approval strategies for Pharmaceutical companies?  

Log in